Table 1.
Behavioral and anatomical validation
| Groups | DAT binding | Number of TH+ cells |
l-Dopa |
|||||
|---|---|---|---|---|---|---|---|---|
| mg | 0 min |
90 min |
||||||
| P | D | P | D | |||||
| Control | C1 | 123.9 | 922 | 0 | 0 | 0 | 0 | |
| C2 | 154.5 | 958 | 0 | 0 | 0 | 0 | ||
| C3 | 134.9 | 1007 | 0 | 0 | 0 | 0 | ||
| C4 | 144.4 | 935 | 0 | 0 | 0 | 0 | ||
| MPTP | M1 | 1.6 | 137 | 9 | 0 | 0 | 0 | |
| M2 | 3.4 | 140 | 9 | 0 | 0 | 0 | ||
| M3 | 2.7 | 74 | 8 | 0 | 0 | 0 | ||
| M4 | 3.5 | 198 | 9 | 0 | 0 | 0 | ||
| MPTP | L1 | 3.9 | 127 | 54 | 9 | 0 | 0 | 0 |
| l-Dopa :no LID | L2 | 2.9 | 237 | 59 | 11 | 0 | 0 | 0 |
| L3 | 4.2 | 169 | 56 | 9 | 0 | 0 | 0 | |
| L4 | 5.3 | 134 | 50 | 8 | 0 | 0 | 0 | |
| MPTP | D1 | 5.6 | 217 | 60 | 9 | 0 | 1 | 4 |
| l-Dopa LID | D2 | 7.7 | 106 | 66 | 8 | 0 | 0 | 3 |
| D3 | 0.8 | 155 | 53 | 7 | 0 | 0 | 4 | |
| D4 | 4.1 | 178 | 50 | 8 | 0 | 0 | 3 | |
| MPTP | D5 | 3.3 | 132 | 52 | 9 | 0 | 1 | 4 |
| l-Dopa LID | D6 | 3.2 | 177 | 51 | 10 | 0 | 0 | 3 |
| HSV-LacZ | D7 | 4.5 | 159 | 58 | 11 | 0 | 1 | 4 |
| MPTP | D8 | 1.5 | 107 | 50 | 11 | 0 | 1 | 4 |
| l-Dopa LID | D9 | 2.0 | 141 | 57 | 10 | 0 | 0 | 4 |
| HSV-RGS9–2 | D10 | 6.4 | 206 | 61 | 10 | 0 | 0 | 3 |
Mean age, 3.05 ± 0.05 years; mean weight, 3.1 ± 0.1 kg. No LID, Nondyskinetic; LID, dyskinetic. Extent of lesion is comparable among the MPTP-lesioned groups at both the striatal [dopamine transporter (DAT) binding, femtomoles per milligram of equivalent tissue] and nigral [tyrosine hydroxylase (TH) immunopositive neurons] levels. l-Dopa dose (in milligrams) is given for each individual as well as their mean parkinsonian (P) and mean dyskinetic (D) scores before administration (0 min) and 90 min after administration.